We scan new podcasts and send you the top 5 insights daily.
Meredith Mazzilli says CoreWeave recently issued convertibles and authorized an at-the-market equity program. It will likely need more capital to grow; if the stock price is low, it must sell more shares to raise the same amount. Project-level financings are ongoing as it expands, so cost of capital and timing matter.
CoreWeave's co-founder explains their innovative financing strategy: bundling GPU infrastructure with long-term revenue contracts to create a financeable asset. This approach, common for power plants, allowed them to raise $8.5B in investment-grade debt for their capital-intensive business.
Meredith Mazzilli explains CoreWeave's delayed draw term loans are backed by long-term customer contracts, often with investment-grade customers like Meta. The risk is execution—building facilities and getting chips producing revenue—while unsecured corporate bonds took the hardest selloff. That distinction matters for credit analysis.
The best time to raise money is when your company doesn't desperately need it. Approaching investors from a position of strength gives you leverage. If you wait until you're desperate, you will be forced to accept expensive, highly dilutive capital.
AI cloud provider CoreWeave is raising billions in debt while being cash-flow negative. This is possible because bond investors are not underwriting CoreWeave's financials, but the creditworthiness of its major customers, like Meta. Meta's ability to pay its bills provides the security for the debt.
Facing capital constraints, biotech companies must make a strategic choice. They can either dilute ownership by raising more venture capital or dilute their pipeline by partnering a secondary asset to fund their lead program. This "equity vs. assets" framework forces a clear-eyed decision on capital strategy.
Nick Del Dio says CoreWeave's project economics are attractive: each dollar invested in compute generates roughly 15 to 20 cents in net present value. That works only if capital markets stay open to fund the upfront spending, he warns.
Financing discussions should carry the same strategic weight as M&A talks. Philip Ross argues the cost of capital from selling stock is often theoretically higher than from selling the entire company. This reframes the decision to dilute ownership for funding as a pivotal choice that boards and management teams should not take lightly.
Tom warns that debt is what eats investment companies like CoreWeave, which people now say might go to zero. He compares AI data-center buildout to past technology booms where interest comes due before revenue catches up. OpenAI has delayed its IPO to 2027, adding pressure to the narrative.
CoreWeave pioneered financing its GPU fleet through special purpose vehicles (SPVs) that isolate assets and contracts. This de-risked structure achieved an investment-grade rating and attracted a new class of conservative investors, like insurance companies, unlocking billions in previously inaccessible capital.
Nick Del Dio says CoreWeave's delayed-draw term loans are secured by customer contracts and GPUs and should remain fundable. The risk sits in parent-level debt, where rates have jumped from 9-10% to about 15%, and convertibles can dilute equity.